Blood-Based Alzheimer's Diagnostics Advance with ALZpath-Abbott and Alzinova-Fujirebio Deals
Key Questions
What partnerships are advancing blood-based Alzheimer's diagnostics?
ALZpath and Abbott have signed a global licensing agreement for a pTau217 antibody test, while Alzinova and Fujirebio signed a Letter of Intent for a blood-based diagnostic. These deals aim to commercialize accessible testing for early detection.
How does the Lumipulse test support Alzheimer's diagnosis?
The FDA-cleared Lumipulse test measures the pTau217/Aβ42 ratio and a new clinical review provides practical guidance for primary care physicians. It could improve screening accessibility and early intervention.
What impact could these developments have on Alzheimer's care?
The partnerships and test guidance may revolutionize early detection by making blood-based testing more widely available. This supports timely diagnosis and better patient outcomes in primary care settings.
Two major partnerships are pushing blood-based Alzheimer's testing toward commercialization. ALZpath and Abbott signed a global licensing agreement for a pTau217 antibody test, while Alzinova and Fujirebio signed a Letter of Intent for a blood-based diagnostic. A new clinical review of the FDA-cleared Lumipulse test (pTau217/Aβ42 ratio) provides practical guidance for primary care. These developments could revolutionize early detection and screening accessibility.